The invention relates to a group of novel electrochromic compounds. More specifically, it relates to benzazoles and condensed azole compounds substituted with one or several pyridinium rings and the use of these compounds as a variable transmittance medium for the manufacture of an optical article, such as an ophthalmic lens.

The invention relates to a group of novel electrochromic compounds. More specifically, it relates to benzazoles and condensed azole compounds substituted with one or several pyridinium rings and the use of these compounds as a variable transmittance medium for the manufacture of an optical article, such as an ophthalmic lens.

The present disclosure relates to a plurality of host materials comprising at least one first host compound and at least one second host compound and an organic electroluminescent device comprising the same. By comprising the specific combination of the compound according to the present disclosure as host materials, an organic electroluminescent device having low driving voltage, high luminous efficiency and long lifespan characteristics can be provided.

A compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same are disclosed: ##STR00001## In Chemical Formula 1, the definition of each group and parameter is as described in the detailed description.

A compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same are disclosed: ##STR00001## In Chemical Formula 1, the definition of each group and parameter is as described in the detailed description.

Disclosed herein is glutathione in conjunction with an isoselenazol or isothiazol derivative, e.g., ebselen or ebsulfur derivative, to treat diabetes, lupus, or other chronic inflammatory disease. The glutathione is preferably provided in a rapid release oral formulation that presents the glutathione for absorption in the first part of the ileum. The isoselenazol or isothiazol derivative is preferably provided in a delayed release formulation to avoid overlapping high enteric concentration. These may be provided within the same unit dosage form.

A condensed cyclic compound includes at least one first repeating unit represented by Formula 1-1 and/or Formula 1-2 and at least one second repeating unit represented by Formula 2-1 and/or Formula 2-2. A light-receiving device includes the condensed cyclic compound in a light-receiving layer of the light-receiving device, and an electronic apparatus and an electronic device include the light-receiving device.

##STR00001##

A condensed cyclic compound includes at least one first repeating unit represented by Formula 1-1 and/or Formula 1-2 and at least one second repeating unit represented by Formula 2-1 and/or Formula 2-2. A light-receiving device includes the condensed cyclic compound in a light-receiving layer of the light-receiving device, and an electronic apparatus and an electronic device include the light-receiving device.

##STR00001##

Compounds, compositions, and methods for the treatment of infections, inflammation, cancers, tinnitus, Meniere's disease, hearing loss, or bipolar disorder, or for providing cytoprotection against Clostridium difficile toxins, are disclosed.

Compounds, compositions, and methods for the treatment of infections, inflammation, cancers, tinnitus, Meniere's disease, hearing loss, or bipolar disorder, or for providing cytoprotection against Clostridium difficile toxins, are disclosed.